Alopecia en pénfigo vulgar
Palabras clave:
PÉNFIGO ALOPECIA AREATA
Resumen
El pénfigo vulgar (PV) es la forma más frecuente, representando el 70% de los casos de pénfigo. Es una enfermedad autoinmune adquirida en la cual los anticuerpos IgG están dirigidos a las proteínas desmosomales para producir la formación de ampollas intraepiteliales mucocutáneas. Las erosiones del cuero cabelludo son una manifestación clínica relativamente común del PV. Sin embargo, la pérdida de cabello progresiva o discretas placas alopécicas se describen raramente en pacientes con PV. Presentamos un caso de PV con pérdida progresiva del cabello y zonas alopécicas.
Citas
(1) Mimouni D, Anhalt G. Pemphigus. Dermatol Ther 2002;15(4):362-8.
(2) Gonçalves GA, Brito MM, Salathiel A, Ferraz T, Alves D, Roselino AM. Incidence of pemphigus vulgaris exceeds that of pemphigus foliaceus in a region where pemphigus foliaceus is endemic: analysis of a 21-year historical series. An Bras Dermatol 2011; 86(6):1109-12.
(3) Mutasim DF, Bilic M, Hawayek LH, Pipitone MA, Sluzevich JC. Immunobullous diseases. J Am Acad Dermatol 2005; 52(6):1029-43.
(4) British Association of Dermatologists, Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149(5):926-37.
(5) Ata-Ali F, Ata-Ali J. Pemphigus vulgaris and mucous membrane pemphigoid: update on etiopathogenesis, oral manifestations and management. J Clin Exp Dent 2011; 3(3):e246-50.
(6) Bystryn JC, Grando SA. A novel explanation for acantholysis in pemphigus vulgaris: the basal cell shrinkage hypothesis. J Am Acad Dermatol 2006; 54(3):513-6.
(7) Chmurova N, Svecova D. Pemphigus vulgaris: a 11-year review. Bratisl Lek Listy 2009; 110(8):500-3.
(8) Veraitch O, Ohyama M, Yamagami J, Amagai M. Alopecia as a rare but distinct manifestation of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2013; 27(1):86-91.
(9) Castellanos IA, Guevara GE. Pénfigo vulgar. Dermatol Rev Mex 2011; 55(2):73-5.
(10) Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity 2012; 45(1):7-35.
(11) Amagai M, Stanley JR. Desmoglein as a target in skin disease and beyond. J Invest Dermatol 2012; 132(3 Pt 2):776-84.
(12) Nagasaka T, Nishifuji K, Ota T, Whittock NV, Amagai M. Defining the pathogenic involvement of desmoglein 4 in pemphigus and staphylococcal scalded skin syndrome. J Clin Invest 2004; 114(10):1484-92.
(13) Hanakawa Y, Li H, Lin C, Stanley JR, Cotsarelis G. Desmogleins 1 and 3 in the companion layer anchor mouse anagen hair to the follicle. J Invest Dermatol 2004; 123(5):817-22.
(14) Banno T, Adachi M, Mukkamala L, Blumenberg M. Unique keratinocyte-specific effects of interferon-gamma that protect skin from viruses, identified using transcriptional profiling. Antivir Ther 2003; 8(6):541-54.
(15) Sánchez Dueñas LE. Dermatoscopía en enfermedades del pelo y la piel cabelluda. Dermatol Rev Mex 2012; 56(3):187-92.
(2) Gonçalves GA, Brito MM, Salathiel A, Ferraz T, Alves D, Roselino AM. Incidence of pemphigus vulgaris exceeds that of pemphigus foliaceus in a region where pemphigus foliaceus is endemic: analysis of a 21-year historical series. An Bras Dermatol 2011; 86(6):1109-12.
(3) Mutasim DF, Bilic M, Hawayek LH, Pipitone MA, Sluzevich JC. Immunobullous diseases. J Am Acad Dermatol 2005; 52(6):1029-43.
(4) British Association of Dermatologists, Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149(5):926-37.
(5) Ata-Ali F, Ata-Ali J. Pemphigus vulgaris and mucous membrane pemphigoid: update on etiopathogenesis, oral manifestations and management. J Clin Exp Dent 2011; 3(3):e246-50.
(6) Bystryn JC, Grando SA. A novel explanation for acantholysis in pemphigus vulgaris: the basal cell shrinkage hypothesis. J Am Acad Dermatol 2006; 54(3):513-6.
(7) Chmurova N, Svecova D. Pemphigus vulgaris: a 11-year review. Bratisl Lek Listy 2009; 110(8):500-3.
(8) Veraitch O, Ohyama M, Yamagami J, Amagai M. Alopecia as a rare but distinct manifestation of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2013; 27(1):86-91.
(9) Castellanos IA, Guevara GE. Pénfigo vulgar. Dermatol Rev Mex 2011; 55(2):73-5.
(10) Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity 2012; 45(1):7-35.
(11) Amagai M, Stanley JR. Desmoglein as a target in skin disease and beyond. J Invest Dermatol 2012; 132(3 Pt 2):776-84.
(12) Nagasaka T, Nishifuji K, Ota T, Whittock NV, Amagai M. Defining the pathogenic involvement of desmoglein 4 in pemphigus and staphylococcal scalded skin syndrome. J Clin Invest 2004; 114(10):1484-92.
(13) Hanakawa Y, Li H, Lin C, Stanley JR, Cotsarelis G. Desmogleins 1 and 3 in the companion layer anchor mouse anagen hair to the follicle. J Invest Dermatol 2004; 123(5):817-22.
(14) Banno T, Adachi M, Mukkamala L, Blumenberg M. Unique keratinocyte-specific effects of interferon-gamma that protect skin from viruses, identified using transcriptional profiling. Antivir Ther 2003; 8(6):541-54.
(15) Sánchez Dueñas LE. Dermatoscopía en enfermedades del pelo y la piel cabelluda. Dermatol Rev Mex 2012; 56(3):187-92.
Publicado
2013-06-30
Cómo citar
1.
Magliano J, Toloza C, Mazzei ME, Durán A, Bruno J, Martínez Asuaga M. Alopecia en pénfigo vulgar. Rev. Méd. Urug. [Internet]. 30 de junio de 2013 [citado 7 de mayo de 2024];29(2):123-6. Disponible en: http://www2.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/290
Sección
Casos Clínicos
